Trial shortfalls – including the early termination of patient enrollment and failure to meet an efficacy endpoint – sank Angel Medical Systems Inc.'s implantable cardiac monitor at an FDA Circulatory System Devices advisory panel meeting.
The 12-member panel unanimously voted that the evidence presented by the company for its AngelMed Guardian System did not show the device is effective or that its benefits outweigh its...